Cas No.: | 1071517-39-9 |
Chemical Name: | N-(3-((4aR,5S,8R,8aS)-1-((4-fluorophenyl)methyl)-1,2,4a,5,6, 7,8,8a-octahydro-4-hydroxy-2-oxo-5,8-methanoquinolin-3-yl)-1,1-dioxido-2H-1,2,4- benzothiadiazin-7-yl) |
Synonyms: | Setrobuvir (USAN), Setrobuvir [USAN], 1071517-39-9, CHEMBL1076263, ANA 598, ANA-598, D10165 |
SMILES: | [H][C@]12[C@](N(CC3=CC=C(F)C=C3)C(C(C(NC4=C5C=C(NS(C)(=O)=O)C=C4)=NS5(=O)=O)=C2O)=O)([H])[C@@H]6CC[C@H]1C6 |
Formula: | C25H25FN4O6S2 |
M.Wt: | 560.617603 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | Setrobuvir (ANA-598) is an experimental drug candidate For the treatment of hepatitis C. It was discovered at Anadys Pharmaceuticals. In 2011, Roche acquired Anadys in order to develop setrobuvir. It is currently in Phase IIb clinical trials, used in combination with interferon and ribavirin, targeting hepatitis C patients with genotype 1.For the detailed information of Setrobuvir, the solubility of Setrobuvir in water, the solubility of Setrobuvir in DMSO, the solubility of Setrobuvir in PBS buffer, the animal experiment (test) of Setrobuvir, the cell expriment (test) of Setrobuvir, the in vivo, in vitro and clinical trial test of Setrobuvir, the EC50, IC50,and Affinity of Setrobuvir, Please contact DC Chemicals. |